Dalteparina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dalteparina" in Italian language version.

refsWebsite

Global rank Italian rank

13nih.gov

4^th place

9^th place

5oadoi.org

799^th place

22^nd place

5doi.org

2^nd place

7^th place

doi.org

dx.doi.org

Douketis J, Cook D, Meade M, et al., Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study, in Arch. Intern. Med., vol. 168, n. 16, settembre 2008, pp. 1805–12, DOI:10.1001/archinte.168.16.1805, PMID 18779469.
Kearon C, Ginsberg JS, Julian JA, et al., Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism, in JAMA, vol. 296, n. 8, agosto 2006, pp. 935–42, DOI:10.1001/jama.296.8.935, PMID 16926353.
Lee AY, Levine MN, Baker RI, et al., Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, in N. Engl. J. Med., vol. 349, n. 2, luglio 2003, pp. 146–53, DOI:10.1056/NEJMoa025313, PMID 12853587.
Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery, in Br J Surg, vol. 92, n. 10, ottobre 2005, pp. 1212–20, DOI:10.1002/bjs.5154, PMID 16175516.
Moore A, Lau E, Yang C, Mackool B, Kuter DJ, Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma, in Am. J. Clin. Oncol., vol. 30, n. 3, giugno 2007, pp. 329–31, DOI:10.1097/01.coc.0000182406.27232.40, PMID 17551316.

nih.gov

ncbi.nlm.nih.gov

Collignon F, Frydman A, Caplain H, et al., Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism), in Thromb. Haemost., vol. 73, n. 4, aprile 1995, pp. 630–40, PMID 7495071.
Frydman A, Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans, in Haemostasis, 26 Suppl 2, 1996, pp. 24–38, PMID 8707165.
Douketis J, Cook D, Meade M, et al., Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study, in Arch. Intern. Med., vol. 168, n. 16, settembre 2008, pp. 1805–12, DOI:10.1001/archinte.168.16.1805, PMID 18779469.
Kearon C, Ginsberg JS, Julian JA, et al., Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism, in JAMA, vol. 296, n. 8, agosto 2006, pp. 935–42, DOI:10.1001/jama.296.8.935, PMID 16926353.
Lee AY, Levine MN, Baker RI, et al., Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, in N. Engl. J. Med., vol. 349, n. 2, luglio 2003, pp. 146–53, DOI:10.1056/NEJMoa025313, PMID 12853587.
Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery, in Br J Surg, vol. 92, n. 10, ottobre 2005, pp. 1212–20, DOI:10.1002/bjs.5154, PMID 16175516.
Tørholm C, Broeng L, Jørgensen PS, et al., Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study, in J Bone Joint Surg Br, vol. 73, n. 3, maggio 1991, pp. 434–8, PMID 1670445.
Lassen MR, Borris LC, Anderson BS, et al., Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study, in Thromb. Res., vol. 89, n. 6, marzo 1998, pp. 281–7, PMID 9669750.
Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD, A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration, in Crit. Care Med., vol. 27, n. 10, ottobre 1999, pp. 2224–8, PMID 10548211.
(ES) Ortín X, Cid J, Ugarriza A, [Dalteparin induced thrombocytopenia. Study of a case], in Med Clin (Barc), vol. 119, n. 10, settembre 2002, pp. 397–8, PMID 12372177.
Ramakrishna R, Manoharan A, Kwan YL, Kyle PW, Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran), in Br. J. Haematol., vol. 91, n. 3, novembre 1995, pp. 736–8, PMID 8555084.
Moore A, Lau E, Yang C, Mackool B, Kuter DJ, Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma, in Am. J. Clin. Oncol., vol. 30, n. 3, giugno 2007, pp. 329–31, DOI:10.1097/01.coc.0000182406.27232.40, PMID 17551316.
Barnes C, Deidun D, Hynes K, Monagle P, Alopecia and dalteparin: a previously unreported association, in Blood, vol. 96, n. 4, agosto 2000, pp. 1618–9, PMID 10979669.

oadoi.org

Douketis J, Cook D, Meade M, et al., Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study, in Arch. Intern. Med., vol. 168, n. 16, settembre 2008, pp. 1805–12, DOI:10.1001/archinte.168.16.1805, PMID 18779469.
Kearon C, Ginsberg JS, Julian JA, et al., Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism, in JAMA, vol. 296, n. 8, agosto 2006, pp. 935–42, DOI:10.1001/jama.296.8.935, PMID 16926353.
Lee AY, Levine MN, Baker RI, et al., Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, in N. Engl. J. Med., vol. 349, n. 2, luglio 2003, pp. 146–53, DOI:10.1056/NEJMoa025313, PMID 12853587.
Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery, in Br J Surg, vol. 92, n. 10, ottobre 2005, pp. 1212–20, DOI:10.1002/bjs.5154, PMID 16175516.
Moore A, Lau E, Yang C, Mackool B, Kuter DJ, Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma, in Am. J. Clin. Oncol., vol. 30, n. 3, giugno 2007, pp. 329–31, DOI:10.1097/01.coc.0000182406.27232.40, PMID 17551316.